Axa S.A. Nektar Therapeutics Transaction History

Axa S.A.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$2.03 - $4.28 $34,713 - $73,188	-17,100 Reduced 4.23%	387,500 $875,000
Q2 2022 Feb 14, 2023	BUY	$3.17 - $6.17 $1.12 Million - $2.18 Million	352,900 Added 682.59%	404,600 $1.54 Million
Q2 2022 Aug 15, 2022	BUY	$3.17 - $6.17 $1.12 Million - $2.18 Million	352,900 Added 682.59%	404,600 $1.54 Million
Q1 2022 Feb 14, 2023	SELL	$4.16 - $13.72 $1.47 Million - $4.84 Million	-352,900 Reduced 87.22%	51,700 $278,000
Q1 2022 May 13, 2022	BUY	$4.16 - $13.72 $215,072 - $709,324	51,700 New	51,700 $278,000

Q4 2018 Feb 13, 2019	SELL	$30.43 - $56.65 $8.29 Million - $15.4 Million	-272,355 Closed	0 $0
Q3 2018 Nov 08, 2018	BUY	$46.46 - $68.49 $12.7 Million - $18.7 Million	272,355 New	272,355 $16.6 Million
Q2 2018 Aug 13, 2018	SELL	$46.25 - $104.45 $656,750 - $1.48 Million	-14,200 Closed	0 $0
Q1 2018 May 14, 2018	BUY	$57.4 - $108.44 $815,080 - $1.54 Million	14,200 New	14,200 $1.51 Million

128

111M

150K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $219M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

Stay updated on Axa S.A. with notifications on news.